Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-01-11
1996-12-03
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548243, 548244, 548246, A61K 3141, C07D26110
Patent
active
055808948
ABSTRACT:
An oxazolyl enaminone is provided having the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of a branched or unbranched alkyl groups containing from 1 to 4 carbon atoms and R.sub.2 is selected from the group consisting of a branched or unbranched alkyl group containing from 1 to 4 carbon atoms, a chloro group, a trifluoromethyl group and a trifluoromethoxy group. Also provided are pharmaceutically accepatable salts and isomers of the above, and pharmaceutical compositions containing the same.
REFERENCES:
patent: 5468775 (1995-11-01), Scott et al.
Edafiogho et al., Synthesis . . . enaminoes., J. Med. Chem. 1992, 35, pp. 2798-2805.
Scott et al., Synthesis . . . enaminones., Further . . . correlations., J. Med. Chem. 1993, 36, pp. 1947-1955.
Molzac et al., The profile . . . rats., Epilepsia, 1993, 1141-1146.
Edafiogho et al., Anticonvulsant . . . (ADD 196022). Curr. Med. Chem., 1994, 1, 161-177.
Edafiogho et al., Nuclear magnetic . . . enaminones. J. Pharm. Sci., 1994, 83, 1155-1170.
Scott et al., Synthesis . . . enaminones. 3. Investigations . . . evaluations., J. Med. Chem., 1995, 38, 4033-4043.
Johnston et al., Central . . . muscimol., Biochem. Pharmacol., 1968, 17, 2488-2489.
Curtis et al., Bicaculline, . . . cat., Brain Res. 1971, 32, 69-96.
Johnston et al., Muscimol . . . brain slices., Psycho pharmacologia, 1971, 22, 230-233.
Schousboe et al., Inhibition . . . compounds., Brain Res., 1978, 153, 623-626.
Krogsgaard-Larsen et al., In Progress in Medicinal Chemistry, vol. 22, 1986, 68-120.
Krogsgaard-Larsen et al., A new class of GABA agonist., Nature (London), 1977, 268, 53-55.
Lin et al., Synthesis . . . activator Abstracts of papers, 208th National Meeting American Chemical Society, 1994.
Spencer et al., Condensation . . . Ketone., J. Org. Chem., 1964, 29, 787-789.
Friary et al., Heterocyclic . . . acids. J. Org. Chem., 1973, 38, 3487-3490.
CA 91: 193411v Isoxazolium salts, Mizugai et al., p. 659, 1979.
Chemical And Pharmacological Properties Of Alkylated 3-Isoxazolidones; S. K. Germane, A. D. Voitenko and Ya. A. Kastron; Institute of Organic Synthesis, Academy of Sciences of the Latvian SSR, Riga. Translated from Khimiko-Farmatsevticheskii Zhurnal, vol. 9, No. 2, pp. 28-30, Feb., 1975.
Comparative pharmacological study of substituted carboxamides upon central nervous system, O. Foussard-Blanpin., Ann. Pharm. Fr., 1982, 40, 339-350.
Chem. Pharm Bull., 34(4), pp. 1643-1655 (1986), Isoxazole Derivatives as Centrally Acting Muscle Relaxants. II., Synthesis and Structure-Activity Relationship of 3-Amino-N-(3-phenyl-5-isoxazolyl)propanamides), Tochiro Tatee, Kazuhisa Narita, Shuji Kurashige, Shinji Ito, Hiroshi Yamanaka, Michinao Mizugaki, Takao Sakamoto and Hideomi Fukuda.
Edafiogho Ivan O.
Roberts Ralph R.
Scott Kenneth R.
Howard University
McKane Joseph K.
LandOfFree
Isoxazolyl enaminones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoxazolyl enaminones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoxazolyl enaminones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-786005